CJC-1295 Ipamorelin Stack: Protocols, Synergy, and Dosing Guide

The CJC-1295 and ipamorelin combination is the most widely researched growth hormone peptide stack in the community, and for a clear mechanistic reason: the two compounds act on different receptors but converge on the same outcome. CJC-1295 primes the pituitary. Ipamorelin pulls the trigger. Together they produce a GH pulse that is meaningfully larger than either compound generates alone.

This guide covers why the synergy works, three dosing protocols organized by research goal, timing strategy, what the research literature says about expected timelines, side effects specific to this combination, and where to source both compounds. If you want the individual compound breakdown first, the CJC-1295 dosage guide and ipamorelin guide cover each peptide in depth before you return here for the stack.

How the Synergy Works

Growth hormone release from the anterior pituitary is governed by two opposing signals. GHRH (growth hormone-releasing hormone) tells the pituitary to prepare and amplify a GH pulse. Ghrelin and its synthetic mimics (the GHRPs) act on a separate receptor called GHS-R1a to directly trigger that release. The natural system uses both signals in concert. A GHRH analog alone increases pulse amplitude but cannot initiate a release on its own schedule. A GHRP alone can trigger a pulse but the magnitude is limited without the priming signal.

CJC-1295 is a synthetic GHRH analog that extends the half-life of the natural GHRH(1-29) sequence. Ipamorelin is a synthetic GHRP that is specifically selected for its receptor selectivity: it stimulates GH release through GHS-R1a with minimal effect on cortisol or prolactin, unlike older GHRPs like GHRP-2 or GHRP-6. When both are present at the same time, the pituitary is simultaneously primed by the GHRH signal and triggered by the ghrelin-receptor signal, producing a synergistic pulse. Research in animal models has shown the combined GH release exceeds the additive effect of each alone.

Which Version of CJC-1295 to Use

This is the most common point of confusion with this stack. CJC-1295 comes in two forms that are dosed completely differently.

CJC-1295 without DAC (also called modified GRF 1-29 or Mod GRF 1-29) has a half-life of roughly 30 minutes. It is designed for pulsatile dosing, timed to match when you want a GH pulse. This is the version used in the stack protocols described below. It mimics the natural pattern of GHRH release.

CJC-1295 with DAC has a half-life of 8 or more days due to the Drug Affinity Complex modification. It is dosed once or twice per week at 1 to 2 milligrams per injection. Because it produces a sustained GHRH signal rather than a pulse, it changes the character of GH release compared to the without-DAC version and is not typically the choice when a pulsatile, physiological-pattern approach is the goal. Some researchers prefer it for the weekly schedule convenience.

The protocols in this guide use CJC-1295 without DAC unless specified otherwise.

Three Dosing Protocols

These protocols reflect what is commonly reported in the research community. They are not medical recommendations.

Protocol 1: Conservative (Entry Research)

This is the starting point for most researchers new to this combination. It minimizes side effect exposure while allowing assessment of individual response.

Protocol 2: Standard (Most Reported)

The most commonly described protocol in the community. Adds a morning or pre-workout injection to increase total daily GH pulse frequency.

Protocol 3: Advanced (Higher Frequency)

Three injections per day is reported by researchers targeting aggressive recovery or body composition goals. Maintaining a fasted window around each injection becomes more important at this frequency.

Timing: Why It Matters for GH Peptides

Growth hormone follows a strong circadian pattern. The largest natural GH pulse of the day occurs during the first phase of slow-wave (deep) sleep, typically in the first few hours after falling asleep. Administering the CJC-1295 and ipamorelin stack 20 to 30 minutes before sleep is designed to amplify this existing pulse rather than introduce a pulse at an arbitrary time.

The second most common timing is the morning, in a fasted state or before training. The rationale is that insulin suppresses GH release: GH secretagogues work better when insulin is low. Eating a large carbohydrate or protein meal 1 to 2 hours before dosing will blunt the GH response. The standard guideline in research protocols is to inject at least 90 minutes after a meal or two or more hours before a meal.

For the pre-workout injection specifically, some researchers prefer to inject 20 to 30 minutes before training to time the GH pulse with the exercise stimulus, which itself drives a natural GH release.

What to Expect: Research Timeline

The effects of GH peptide stacks accumulate over weeks rather than appearing overnight. The pattern reported most often in the community follows a rough progression.

Weeks 1 to 2. Sleep quality improvements are the most commonly noted early change. Researchers report deeper sleep, more vivid dreams, and reduced time to fall asleep. This is consistent with the role of GH in sleep architecture. Some people notice a mild flush or warmth shortly after injection, which is a normal transient vasodilatory response.

Weeks 3 to 6. Recovery from training starts to noticeably accelerate. Muscle soreness clears faster. Some mild water retention may occur as GH drives fluid shifts in connective tissue. Body composition changes are not yet typically visible but some researchers report subtle reductions in subcutaneous fat around the midsection.

Weeks 8 to 16. Body composition changes become more apparent. The combination of better sleep, improved recovery, and GH-driven lipolytic effects tends to produce incremental reductions in body fat and modest increases in lean tissue, especially when combined with consistent training. Skin quality and joint comfort are also commonly mentioned in longer protocols.

The timeline assumes the peptides are pharmaceutical-grade and properly reconstituted. Underdosed or degraded product produces none of these effects, which is why sourcing is not a secondary consideration.

Side Effects

Ipamorelin is specifically chosen for this stack because of its side effect profile relative to other GHRPs. GHRP-2 and GHRP-6 both significantly stimulate cortisol and prolactin, which limits their practical use. Ipamorelin does not. At research doses, cortisol and prolactin elevations are minimal, which is a clinically meaningful advantage for anyone sensitive to those hormones.

The side effects that do occur with the CJC + ipamorelin stack are largely GH-driven rather than peptide-specific:

• Water retention. GH promotes sodium and water retention, particularly in connective tissue. This can manifest as a slightly bloated appearance or minor weight gain on the scale that does not reflect fat. It typically resolves after the first few weeks as the body adapts or when the cycle ends.
• Transient numbness or tingling. Carpal tunnel-like symptoms in the hands and fingers are a known GH-related side effect at higher doses. If this becomes uncomfortable, reducing the dose or frequency usually resolves it.
• Flushing or warmth after injection. A brief flush, usually lasting 5 to 20 minutes after injection, is a common and benign response. It indicates the peptide is active. It fades with subsequent injections in most people.
• Headache. Mild, transient headaches are occasionally reported, particularly early in a protocol. Staying well hydrated helps.
• Injection site irritation. Minor redness, itching, or bruising at the subcutaneous injection site. Rotating sites and using appropriate needle length minimizes this.

At the conservative and standard protocol doses, serious adverse events are not commonly reported in the community. That said, long-term human safety data for this combination is limited, and the risk profile at higher doses or very long cycles is not well characterized.

Adding BPC-157 or TB-500 to the Stack

For researchers focused on injury recovery, the CJC-1295 and ipamorelin base stack is sometimes extended with healing-focused peptides. The GH stimulus from the stack supports collagen synthesis and tissue remodeling, while BPC-157 and TB-500 act through separate angiogenic and actin-binding mechanisms.

BPC-157 is most relevant for gut lining integrity, tendon-to-bone attachment sites, and localized inflammatory issues. TB-500 targets systemic repair and flexibility, with a particular association with muscle fiber regeneration. Our recovery peptide guide covers how these fit together.

Where to Source CJC-1295 and Ipamorelin

Both compounds need to arrive as lyophilized powder with a batch-specific certificate of analysis showing purity and sterility testing. A COA on a company's website that does not reference a specific lot number is not a meaningful quality guarantee. Batch-level documentation is the minimum standard worth caring about.

Two vendors on our 2026 vendor scorecard carry both CJC-1295 (without DAC) and ipamorelin with batch documentation:

• Amino Club stocks CJC-1295 (no DAC) and ipamorelin as separate vials, with published lab results per batch. Pricing is competitive and they frequently carry both in stock.
• Pantheon Peptides also carries CJC-1295 (no DAC) and ipamorelin with batch certificates and is a commonly cited option in the community for reliability.
• Apollo Peptides offers CJC-1295 and ipamorelin and is worth comparing on price when both are in stock.

For reconstitution, use bacteriostatic water. Standard reconstitution of a 5mg CJC-1295 vial with 2mL of BAC water gives 2.5mg/mL (2500 mcg/mL), meaning 0.04mL on an insulin syringe delivers 100 mcg. Our peptide reconstitution calculator has the reference tables for every common vial size and dose. Our storage guide covers what to do once the vials are reconstituted.

Key Takeaways

• CJC-1295 (GHRH analog) and ipamorelin (selective GHRP) act on different receptors to produce a synergistic GH pulse larger than either compound alone.
• Ipamorelin is chosen for its minimal cortisol and prolactin stimulation, which distinguishes it from older GHRPs.
• Use CJC-1295 without DAC for pulsatile protocols; the DAC version has an 8-day half-life and is dosed entirely differently.
• The pre-sleep injection is the highest priority timing, amplifying the natural nocturnal GH pulse. Low-insulin windows matter for all injections.
• Effects accumulate over weeks: sleep quality first, then recovery, then body composition changes.
• Common side effects are GH-driven: transient water retention, flushing, and occasional tingling. Ipamorelin's selectivity keeps cortisol and prolactin effects minimal.
• Source from vendors with batch-specific certificates of analysis. Both compounds need lyophilized powder from a verified supply chain.

Frequently Asked Questions